In a research report published today, J.P.
In a research report sent to investors today, Cowen analyst Phil Nadeau maintained an Outperform rating on Gilead Sciences (NASDAQ:GILD) with a price …
This has not been an easy year for hedge funds. The most popular hedge fund strategy, long/short equity, which usually churns out an …
Let me start with one admission: I have no idea when the current slide in the oil price will end. I won’t insult …
In a research report published today, Deutsche Bank analyst Robyn Karnauskas maintained a Buy rating on Gilead Sciences (NASDAQ:GILD), but reduced her price …
Every major oil producer will be cash flow negative next year if oil prices stay where they are today, according to research from …
William Blair analyst John Sonnier is out with a research note on Gilead Sciences (NASDAQ:GILD), reiterating an Outperform rating, following the announcement from Express Scripts (NASDAQ:ESRX) …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price target, …
In a research report published Friday, Maxim Group analyst Jason Kolbert downgraded shares of Ocata Therapeutics (NASDAQ:OCAT) from Buy to Hold, as the company plans to raise …
In a research report sent to investors today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a …
